

Luca Spiezia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9259373/publications.pdf>

Version: 2024-02-01

146
papers

3,973
citations

136885

32
h-index

149623

56
g-index

152
all docs

152
docs citations

152
times ranked

5190
citing authors

#	ARTICLE	IF	CITATIONS
1	Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-Induced Coagulation: Additive Effects of Aspirin. <i>Thrombosis and Haemostasis</i> , 2022, 122, 092-104.	1.8	11
2	Risk Factors for Post-Thrombotic Syndrome in Patients With a First Proximal Deep Venous Thrombosis Treated With Direct Oral Anticoagulants. <i>Angiology</i> , 2022, 73, 649-654.	0.8	6
3	Cardiac injury and COVID-19 associated coagulopathy in patients with acute SARS-CoV-2 pneumonia: A rotational thromboelastometry study. <i>Advances in Medical Sciences</i> , 2022, 67, 39-44.	0.9	4
4	Letter to the editor: Is PAI-1 a thrombotic biomarker in NASH cirrhosis?. <i>Hepatology</i> , 2022, 76, E16-E17.	3.6	1
5	Protein C or Protein S deficiency associates with paradoxically impaired platelet-dependent thrombus and fibrin formation under flow. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12678.	1.0	2
6	Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1352-1360.	1.8	6
7	Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation. <i>Viruses</i> , 2022, 14, 737.	1.5	7
8	Staging the pre-procedural prophylaxis in decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2022, 54, 1130-1132.	0.4	5
9	Mechanisms of thrombosis in pancreatic ductal adenocarcinoma. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101346.	0.7	9
10	Are thromboelastometric and thromboelastographic parameters associated with mortality in septic patients? A systematic review and meta-analysis. <i>Journal of Critical Care</i> , 2021, 61, 5-13.	1.0	14
11	Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia. <i>Blood</i> , 2021, 137, 2383-2393.	0.6	20
12	Cardiopulmonary bypass-induced coagulopathy in pediatric patients: The role of platelets in postoperative bleeding. A preliminary study. <i>Artificial Organs</i> , 2021, 45, 852-860.	1.0	9
13	Thrombin generation in patients with COVID-19 with and without thromboprophylaxis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1323-1330.	1.4	40
14	Use of Glucocorticoids and Risk of Venous Thromboembolism: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 654-661.	1.5	19
15	PO-29 Plasma levels of procoagulant and anticoagulant factors in patients with acute cancer-associated thrombosis. <i>Thrombosis Research</i> , 2021, 200, S32.	0.8	0
16	Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Liver International</i> , 2021, 41, 2455-2466.	1.9	29
17	Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2021, 53, 879-888.	0.4	17
18	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. <i>Hepatology Communications</i> , 2021, 5, 1987-2000.	2.0	16

#	ARTICLE	IF	CITATIONS
19	Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study. <i>Thrombosis Research</i> , 2021, 205, 24-28.	0.8	22
20	ABO blood groups and the risk of retinal vein occlusion. <i>Internal and Emergency Medicine</i> , 2021, 16, 1387-1390.	1.0	1
21	Post-operative hypercoagulable whole blood profiles in patients undergoing open thoracotomy vs video-assisted thoracoscopic surgery. <i>Blood Transfusion</i> , 2021, 19, 144-151.	0.3	4
22	Potential Association between Distal Deep Vein Thrombosis and Asymptomatic Atherosclerosis. <i>TH Open</i> , 2021, 05, e585-e590.	0.7	1
23	Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 770463.	1.8	27
24	The prognostic role of ThromboDynamic Index in patients with severe sepsis. <i>Internal and Emergency Medicine</i> , 2020, 15, 163-168.	1.0	4
25	Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2020, 40, 913-920.	1.9	12
26	More Severe Hypercoagulable State in Acute COVID-19 Pneumonia as Compared With Other Pneumonia. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 696-702.	1.2	12
27	COVID-19 and Venous Thromboembolism in Intensive Care or Medical Ward. <i>Clinical and Translational Science</i> , 2020, 13, 1108-1114.	1.5	46
28	Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1173-1181.	1.8	41
29	Platelet-primed interactions of coagulation and anticoagulation pathways in flow-dependent thrombus formation. <i>Scientific Reports</i> , 2020, 10, 11910.	1.6	21
30	Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study. <i>Journal of the American Heart Association</i> , 2020, 9, e018917.	1.6	31
31	How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 795-798.	1.0	5
32	Different Hypercoagulable Profiles in Patients with COVID-19 Admitted to the Internal Medicine Ward and the Intensive Care Unit. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1474-1477.	1.8	233
33	Acquired haemophilia A, concomitant acute myocardial infarction and urgent major surgery: How to successfully treat a critical patient with rFVIII (Obizur®). <i>Thrombosis Research</i> , 2020, 195, 125-127.	0.8	5
34	Thrombin generation and thromboelastometry in monitoring the in-vitro reversal of warfarin: a comparison between 3-factor and 4-factor prothrombin complex concentrates. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 127-131.	0.5	4
35	Acute pulmonary embolism in COVID-19 related hypercoagulability. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 223-226.	1.0	21
36	Dengue fever as a rare cause of pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 690-693.	1.0	3

#	ARTICLE	IF	CITATIONS
37	Thrombotic risk following video-assisted thoracoscopic surgery versus open thoracotomy: a systematic review and meta-analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 30, 573-581.	0.5	3
38	The haemostatic system in acromegaly: a single-centre caseâ€“control study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1009-1018.	1.8	2
39	COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. <i>Thrombosis and Haemostasis</i> , 2020, 120, 998-1000.	1.8	553
40	MAC Projectâ€“Monitoring Anticoagulant Therapy Observational Study: Rationale and Protocol. <i>Frontiers in Medicine</i> , 2020, 7, 584459.	1.2	3
41	Whole-blood hypocoagulable profile correlates with a greater risk of death within 28 days in patients with severe sepsis. <i>Korean Journal of Anesthesiology</i> , 2020, 73, 224-231.	0.9	13
42	Tailored prophylaxis with rFXIII (NovoThirteen [®]) in a young girl with severe FXIII deficiency and previous cephalohaematoma. <i>Haemophilia</i> , 2019, 25, e206-e208.	1.0	2
43	Thrombophilia, risk factors and prevention. <i>Expert Review of Hematology</i> , 2019, 12, 147-158.	1.0	54
44	Thromboelastometry profiles after â€œin vitroâ€“addition of a new plasmaâ€“derived factor V concentrate to whole blood from para haemophilia patients. <i>Haemophilia</i> , 2019, 25, e38-e42.	1.0	2
45	Levels of circulating microparticles in septic shock and sepsis-related complications: a case-control study. <i>Minerva Anestesiologica</i> , 2019, 85, 625-634.	0.6	26
46	â€œIn vitroâ€“correction of the severe factor V deficiencyâ€“related coagulopathy by a novel plasmaâ€“derived factor V concentrate. <i>Haemophilia</i> , 2018, 24, 648-656.	1.0	18
47	ABO blood group and the risk of post-thrombotic syndrome. <i>Annals of Hematology</i> , 2018, 97, 1057-1060.	0.8	7
48	Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 501-504.	0.6	5
49	On-treatment platelet reactivity in peripheral and coronary blood in patients undergoing primary PCI for ST-segment elevation myocardial infarction (STEMI). <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 281-286.	0.6	1
50	Activated Plateletâ€“Derived and Leukocyteâ€“Derived Circulating Microparticles and the Risk of Thrombosis in Heparinâ€“Induced Thrombocytopenia: A Role for PF4â€“Bearing Microparticles?. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 334-341.	0.7	34
51	Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 450.	1.7	51
52	Association between ABO blood group and bleeding phenotype in patients with mild rare bleeding disorders. <i>Haemophilia</i> , 2018, 24, e428-e430.	1.0	3
53	New generation flow-cytometry to measure circulating microvesicles in cancer. <i>Thrombosis Research</i> , 2018, 164, S242-S243.	0.8	0
54	The diagnostic challenge: are we missing pulmonary embolism diagnosis in patients with syncope?. <i>Internal and Emergency Medicine</i> , 2018, 13, 965-969.	1.0	0

#	ARTICLE	IF	CITATIONS
55	Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2018, 38, 2210-2218.	1.9	39
56	Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. <i>Hematological Oncology</i> , 2018, 36, 801-803.	0.8	4
57	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2017, 49, 440-445.	0.4	66
58	Modulating thrombotic diathesis in hereditary thrombophilia and antiphospholipid antibody syndrome: a role for circulating microparticles?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 934-943.	1.4	5
59	The current understanding of trauma-induced coagulopathy (TIC): a focused review on pathophysiology. <i>Internal and Emergency Medicine</i> , 2017, 12, 981-991.	1.0	23
60	Predictors of postoperative bleeding in children undergoing cardiopulmonary bypass: A preliminary Italian study. <i>Thrombosis Research</i> , 2017, 153, 85-89.	0.8	8
61	Thromboelastometry guided fibrinogen replacement therapy in cardiac surgery: a retrospective observational study. <i>Journal of Anesthesia</i> , 2017, 31, 286-290.	0.7	14
62	Factor VIIa-antithrombin complex: a possible new biomarker for activated coagulation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 484-488.	1.4	13
63	Factor V Leiden paradox and the occurrence of distal vein thrombosis in a large cohort of thrombotic patients. <i>Thrombosis Research</i> , 2017, 156, 20-22.	0.8	3
64	Point-of-care management of fulminant hyperfibrinolysis in the Emergency Department after hanging trauma. <i>Anaesthesia Cases</i> , 2016, 4, 97-101.	0.0	1
65	Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S. <i>Thrombosis and Haemostasis</i> , 2016, 115, 81-88.	1.8	36
66	Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2016, 48, e37.	0.4	0
67	New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1022-1029.	1.1	49
68	Microparticles as biomarkers of venous thromboembolic events. <i>Biomarkers in Medicine</i> , 2016, 10, 743-755.	0.6	46
69	Endocytosis of exogenous factor V by <i>in vivo</i> differentiated megakaryocytes from patients with severe parahaemophilia. <i>British Journal of Haematology</i> , 2016, 175, 517-524.	1.2	6
70	Diagnosis and management of factor V Leiden. <i>Expert Review of Hematology</i> , 2016, 9, 1139-1149.	1.0	39
71	Thromboelastometry profiles in patients undergoing thrombolytic therapy for acute ischaemic stroke. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1231-1234.	1.8	12
72	Perioperative coagulation assessment of patients undergoing major elective orthopedic surgery. <i>Internal and Emergency Medicine</i> , 2016, 11, 793-801.	1.0	18

#	ARTICLE	IF	CITATIONS
73	Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. <i>Thrombosis Research</i> , 2016, 143, 118-121.	0.8	29
74	Short-term exposure to high levels of air pollution (nickel) and the risk of acute unprovoked proximal deep vein thrombosis in the legs. <i>Internal and Emergency Medicine</i> , 2016, 11, 159-162.	1.0	6
75	The Coagulative Profile of Cyanotic Children Undergoing Cardiac Surgery: The Role of Whole Blood Preoperative Thromboelastometry on Postoperative Transfusion Requirement. <i>Artificial Organs</i> , 2016, 40, 698-705.	1.0	18
76	Dynamics of circulating microparticles in obesity after weight loss. <i>Internal and Emergency Medicine</i> , 2016, 11, 695-702.	1.0	34
77	Coagulation and Point of Care in Clinical Practice: History. , 2016, , 67-68.		0
78	Activated prothrombin complex concentrate (FEIBA [®]) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study. <i>Thrombosis Research</i> , 2015, 136, 1299-1302.	0.8	17
79	Optimal duration of anticoagulation. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1210-1215.	1.8	21
80	Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events. <i>Thrombosis and Haemostasis</i> , 2015, 113, 85-96.	1.8	82
81	The impact of disseminated intravascular coagulation on the outcome of cancer patients with venous thromboembolism. <i>Blood Coagulation and Fibrinolysis</i> , 2015, 26, 709-711.	0.5	5
82	Whole blood thromboelastometry profiles in women with preeclampsia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1793-8.	1.4	16
83	Circulating microparticles in umbilical cord blood in normal pregnancy and pregnancy with preeclampsia. <i>Thrombosis Research</i> , 2015, 136, 427-431.	0.8	32
84	Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. <i>Clinica Chimica Acta</i> , 2015, 446, 201-205.	0.5	38
85	Origin and levels of circulating microparticles in normal pregnancy: A longitudinal observation in healthy women. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 487-495.	0.6	16
86	The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti- β 2 glycoprotein I antibodies. A comparison with a homemade ELISA method. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1083-9.	1.4	32
87	Hypercoagulability detected by whole blood thromboelastometry (ROTEM [®]) and impedance aggregometry (MULTIPLATE [®]) in obese patients. <i>Thrombosis Research</i> , 2015, 135, 548-553.	0.8	59
88	Role of factor V Leiden polymorphism or G20210A prothrombin variant in patients with sudden sensorineural hearing loss: A meta-analysis of the literature. <i>Thrombosis Research</i> , 2015, 135, 565-567.	0.8	4
89	Could Hemorrhagic and Thrombotic Risk Due to Peg-Asparaginase be Identified By Coagulative Tests Using Fibtetm and Antithrombin Levels? A Single Centre Study. <i>Blood</i> , 2015, 126, 2305-2305.	0.6	0
90	Management of severe bleeding in a ruptured extrauterine pregnancy. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 176-179.	0.5	7

#	ARTICLE	IF	CITATIONS
91	Short-term exposure to high levels of air pollution as a risk factor for acute isolated pulmonary embolism. <i>Thrombosis Research</i> , 2014, 134, 259-263.	0.8	23
92	Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis?. <i>Internal and Emergency Medicine</i> , 2014, 9, 397-403.	1.0	15
93	Circulating microparticles in carriers of prothrombin G20210A mutation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 432-437.	1.8	14
94	Evaluation of a procoagulant phospholipid functional assay as a routine test for measuring circulating microparticle activity. <i>Blood Coagulation and Fibrinolysis</i> , 2014, 25, 534-537.	0.5	20
95	Whole blood rotation thromboelastometry (ROTEM®) profiles in subjects with non-neoplastic portal vein thrombosis. <i>Thrombosis Research</i> , 2013, 132, e131-e134.	0.8	39
96	Association between increased FVIIa-antithrombin complex/FVIIa ratio and pre-eclampsia. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2013, 26, 1352-1354.	0.7	4
97	Factor VIIa-antithrombin complexes in patients with non-neoplastic portal vein thrombosis with and without cirrhosis. <i>International Journal of Laboratory Hematology</i> , 2013, 35, 101-105.	0.7	7
98	Identification of a novel frameshift mutation causing a premature stop codon in a young Nigerian man with type I antithrombin deficiency. <i>Thrombosis Research</i> , 2013, 131, 463-465.	0.8	4
99	Thrombin Activatable Fibrinolysis inhibitor in Cancer Patients with and without Venous Thromboembolism. <i>Thrombosis Research</i> , 2013, 132, 484-486.	0.8	7
100	“Hypocoagulable” thromboelastography profiles in patients with cyanotic congenital heart disease: Facts or technical artifacts?. <i>International Journal of Cardiology</i> , 2013, 168, 2914.	0.8	8
101	Treatment of venous thromboembolism: the single-drug approach. <i>Clinical Practice (London, England)</i> , 2013, 13(10), 107-111.	0.1	1
102	Thromboelastographic evaluation of coagulative profiles in pig-to-monkey kidney xenotransplantation. <i>Xenotransplantation</i> , 2013, 20, 89-99.	1.6	9
103	Antisense-based RNA therapy of factor V deficiency: in vitro and ex vivo rescue of a F5 deep-intronic splicing mutation. <i>Blood</i> , 2013, 122, 3825-3831.	0.6	17
104	Factor IX activity/antigen ratio and the risk of first unprovoked venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013, 109, 755-756.	1.8	2
105	ABO blood groups and the risk of venous thrombosis in patients with inherited thrombophilia. <i>Blood Transfusion</i> , 2013, 11, 250-3.	0.3	32
106	Effect on Thrombin Generation of the “In Vitro” Addition of Low-Dose LMWH to Plasma of Healthy Pregnant and Nonpregnant Women. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2012, 18, 331-333.	0.7	7
107	Factor VIIa-antithrombin complexes plasma levels in cancer patients with and without thrombosis. <i>Thrombosis Research</i> , 2012, 129, 818-819.	0.8	3
108	Reprint of: Factor VIIa-AT complex plasma levels and arterial thrombosis. <i>Thrombosis Research</i> , 2012, 130, 141.	0.8	3

#	ARTICLE	IF	CITATIONS
109	Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2012, 108, 633-639.	1.8	27
110	Contribution of fibrinolytic tests to the differential diagnosis of veno-occlusive disease complicating pediatric hematopoietic stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2012, 58, 791-797.	0.8	19
111	Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. <i>Haemophilia</i> , 2012, 18, 39-45.	1.0	51
112	Whole blood rotation thromboelastometry (ROTEM [®]) in nine severe factor V deficient patients and evaluation of the role of intraplatelets factor V. <i>Haemophilia</i> , 2012, 18, 463-468.	1.0	24
113	Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. <i>Thrombosis Research</i> , 2011, 127, 473-477.	0.8	122
114	Factor VIIa-antithrombin complexes in children with ischemic stroke. <i>Thrombosis Research</i> , 2011, 128, 303-304.	0.8	10
115	Factor VIIa-AT complex plasma levels and arterial thrombosis. <i>Thrombosis Research</i> , 2011, 128, 507.	0.8	1
116	Effects of Long-Term Administration of Recombinant Human Protein C in Xenografted Primates. <i>Transplantation</i> , 2011, 91, 161-168.	0.5	13
117	The hazard of comparing apples and oranges: The proper indication for the use of recombinant activated clotting factor VII in cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, 1588-1589.	0.4	3
118	Freedom Solo Stentless Aortic Valve: Quantitative and Qualitative Assessment of Thrombocytopenia. <i>Annals of Thoracic Surgery</i> , 2011, 92, 1935.	0.7	13
119	Outcome of Long-Term Prophylaxis After Cerebral Hemorrhage in a Patient With Severe Hemophilia B. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2011, 17, 535-538.	0.7	1
120	Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. <i>Haematologica</i> , 2010, 95, 1563-1571.	1.7	47
121	Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms. <i>Blood</i> , 2010, 115, 879-886.	0.6	121
122	Upper extremity deep vein thrombosis. <i>Internal and Emergency Medicine</i> , 2010, 5, 103-109.	1.0	38
123	Thrombophilia and the risk of post-thrombotic syndrome: retrospective cohort observation. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 211-213.	1.9	18
124	Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1188-1192.	1.8	32
125	Reference values for thromboelastometry (ROTEM [®]) in cynomolgus monkeys (<i>Macaca fascicularis</i>). <i>Thrombosis Research</i> , 2010, 126, e294-e297.	0.8	20
126	Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from mixed type I/III families. <i>Haematologica</i> , 2010, , .	1.7	2

#	ARTICLE	IF	CITATIONS
127	Potential Role of Thrombelastography in the Monitoring of Acquired Factor VIII Inhibitor Hemophilia A: Report on a 78-year-old Woman With Life-threatening Bleedings. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 470-476.	0.7	7
128	The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease. <i>American Journal of Hematology</i> , 2009, 84, 594-596.	2.0	20
129	X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua). <i>New England Journal of Medicine</i> , 2009, 361, 1671-1675.	13.9	298
130	Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 773-777.	1.9	28
131	Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. <i>Blood</i> , 2008, 112, 3615-3623.	0.6	135
132	Thrombophilia as a predictor of persistent residual vein thrombosis. <i>Haematologica</i> , 2008, 93, 479-480.	1.7	25
133	Whole blood coagulation assessment using rotation thrombelastogram thromboelastometry in patients with acute deep vein thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 355-360.	0.5	43
134	Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1106-1110.	1.8	82
135	Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1106-10.	1.8	21
136	Inherited Thrombophilia and Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 700-708.	1.5	62
137	Difficulties in the Mutation Analysis of Plasminogen Gene: A Study in Two Patients with Ligneous Conjunctivitis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2006, 12, 77-84.	0.7	5
138	Isolation and Characterization of an Antifactor VIII Antibody from a Patient with Acquired Hemophilia A and a Severe Hemorrhagic Syndrome.. <i>Blood</i> , 2006, 108, 4073-4073.	0.6	0
139	Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population. <i>Thrombosis and Haemostasis</i> , 2005, 93, 682-689.	1.8	19
140	The PAI-I gene 4G/5G Polymorphism and Deep Vein Thrombosis in Patients with Inherited Thrombophilia. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 299-307.	0.7	64
141	Influence of the Alu-Repeat I/D Polymorphism in t-PA Gene Intron 8 on the Stimulated t-PA Release After Venous Occlusion. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 63-69.	0.7	9
142	Proposal of a Flow Chart for Thrombosis-Free Oral Contraceptive Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 33-37.	0.7	3
143	Changes in Prescription Patterns of Oral Contraceptives in a Northern Italian Province: Relation With Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2003, 9, 125-130.	0.7	3
144	Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy. <i>Transplantation</i> , 2003, 75, 994-998.	0.5	30

#	ARTICLE	IF	CITATIONS
145	IMPROVED FIBRINOLYTIC CAPACITY AFTER WITHDRAWAL OF STEROID IMMUNOSUPPRESSION IN RENAL TRANSPLANT RECIPIENTS1. Transplantation, 2000, 69, 2116-2121.	0.5	31
146	COVID-19 and Venous Thromboembolism in Intensive Care or Medical Ward. SSRN Electronic Journal, 0, , .	0.4	0